<DOC>
	<DOC>NCT01784757</DOC>
	<brief_summary>A study to investigate which of two different tablet formulations of ODM-201 is best suited for use in the further development of the compound in the treatment of metastatic chemotherapy-naive castration-resistant prostate cancer. Patients successfully completing the bioavailability study will be able to receive further treatment with the current capsule formulation of ODM-201 until progression of their disease with the safety and tolerability of ODM-201 being assessed throughout.</brief_summary>
	<brief_title>Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Written informed consent (IC) obtained. Histologically confirmed adenocarcinoma of prostate Progressive metastatic disease Ongoing androgen deprivation therapy with a luteinising hormonereleasing hormone (LHRH) analogue or antagonist or bilateral orchiectomy Adequate bone marrow, hepatic and renal function Able to swallow the ODM201 whole as a capsule or tablet. Previous chemotherapy for prostate cancer. Known metastases in the brain. History of other malignancy within the previous 5 years, except a basal cell carcinoma of skin. Known gastrointestinal condition that can significantly affect the absorption of the study treatment.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>